379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor

379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor

Bibliographic Details
Main Authors: Gareth Betts, Natalie Bath, Mark Dudley, Tanner Johanns, Ahmed Galal, Samuel Saibil, Adrian Sacher, Spinner William, Alex Tipping, Jessica Tucci, Raymond Luke, Trupti Trivedi, Quan Lin, Karen Miller
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items